#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Transplant rejection Urethral valves Myocarditis Neonatal alloimmune thrombocytopenia Pancreatic neuroendocrine tumour Cystic fibrosis Chronic myeloid leukaemia Vascular calcification Congenital ectodermal dysplasia Osteosarcoma Bladder cancer Heritable pulmonary arterial hypertension Polyneuropathy Metachromatic leukodystrophy Activated PI3 kinase delta syndrome More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Basic Information Congenital nephrogenic diabetes insipidus – Basic Information Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Leiomyosarcoma – Basic Information X-linked lymphoproliferative syndrome – Life with Disease Urea cycle disorder CADASIL – Diagnostics Retinitis pigmentosa – Diagnostics Primary biliary cholangitis – Treatment Chordoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tigecycline Ecoo75 Trimethoprim Vinflunine GSKVX000000048111 Cobamamide Mva-209-Fsp-B3 Leriglitazone Ibuprofen Ziclumeran OLVEREMBATINIB Efepoetin Alfa DIMENHYDRINATE Biotin Ab-1002 Bepranemab Tiapride Balstilimab STREPTOCOCCUS PYOGENES Antiemetics And Antinauseants More therapies…

    Learn about Your Condition

    Leiomyosarcoma recurrent Oesophageal food impaction Left ventricular failure Propionic acidaemia Pancreatic carcinoma Plasma cell myeloma Immune-mediated myositis Osteonecrosis of jaw Neuralgia Vaginal infection Adrenoleukodystrophy Low cardiac output syndrome Keratosis follicular Hyperthyroidism Carotid artery stenosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

    Recruiting

    4 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia France Germany Greece +5

  • Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • 4-[4-CYANO-2-[[(1’R,4S)-6-(PROPAN-2-YLCARBAMOYL)SPIRO[2,3-DIHYDROCHROMENE-4,2′-CYCLOPROPANE]-1′-CARBONYL]AMINO]PHENYL]BUTANOIC ACID
    • Calcium Folinate
    • Bevacizumab
    France Italy Spain

  • Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Trastuzumab Deruxtecan
    France Germany Italy Spain

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Cetirizine Dihydrochloride
    • Codeine Phosphate
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of Mitazalimab Injection Treatment for Patients with High-Risk Oral Potentially Malignant Disorders

    Recruiting

    2 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • Mitazalimab
    Italy

  • Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • RO7837195
    Czechia France Germany Italy Poland

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

    Recruiting

    3 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • Bi 1291583
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Arginine Hydrochloride
    • Dimeticone
    • Lysine Hydrochloride
    France Germany Hungary Italy The Netherlands Poland +1

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15
Previous Page
1 … 10 11 12 13 14 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!